Daewoong Pharmaceutical said Monday the company will develop a microneedle-based obesity treatment drug.

The South Korean pharmaceutical company aims to start a phase 1 clinical trial next year and launch the treatment in 2028.

Daewoong Pharmaceutical’s new obesity treatment will contain a synthetic peptide semaglutide, which is similar to glucagon-like peptide-1 (GLP-1), a hormone produced in the gut released in response to food to reduce appetite and the release of insulin.

The patch-type obesity treatment, measuring 1 square centimeter, will use drug-loaded dissolvable microneedles to penetrate the outer layer of the skin to deliver drug ingredients to the patient’s body. The company said patients will be able to easily administer the treatment and minimize injections-associated fears involving existing injection-type GLP-1 agonists.

“The patch-type obesity treatment will increase overall medication adherence of patients with obesity who have to take the treatment on a regular basis,” an official from Daewoong Pharmaceutical said. Daewoong Pharmaceutical said patients will need to use its patch-type obesity treatment just once a week.

Daewoong Pharmaceutical added the new treatment also aims to eliminate common side effects like skin swelling or lumps to improve the treatment experience.

For the development of the patch-type obesity treatment, Daewoong Pharmaceutical will also apply its own microneedle platform technology known as closed-packed aero-pressured microneedle (CLOPAM).

“While microneedles have been widely used in cosmetics, their application in medicine has been limited due to issues involving drug capacity and transdermal absorption. Daewoong Pharmaceutical’s CLOPAM technology is designed to ensure efficient drug delivery and minimize drug loss,” the official said.

Daewoong Pharmaceutical's microneedle platform technology will allow patients to store and use the treatment at room temperature, the official added.

Daewoong Pharmaceutical's microneedle platform has been developed by its research and development unit Daewoong Therapeutics. Daewoong Pharmaceutical has filed 23 patents in South Korea and registered six international patents for the microneedle technology. The company said it has received a proposal from a global pharmaceutical firm to develop other microneedle-based medications.

With the development of patch-type obesity treatment, Daewoong aims to enter the rapidly growing global obesity treatment market, it said. The global market for obesity treatments is expected to grow to 104 trillion won ($80 billion) by 2030, the firm said, quoting data from Morgan Stanley.

"Daewoong Pharmaceutical will push ahead with the development of the new patch-type obesity treatment for patients with unmet medical needs," Daewoong Pharmaceutical CEO Jeon Seung-ho said.

Meanwhile, Daewoong Pharmaceutical is also conducting studies to develop its new diabetes drug Enblo as a potential treatment for obesity.

• ·Kolmar BNH to ramp up production with new plant
• ·N.SSign to resume album promotion without Doha
• ·33년 경찰 경력 내세워…“안심구청장 누구입니까”
• ·Uncertainties remain for Samsung, SK after US eases export controls
• ·[Korea Beyond Korea] Korean Studies gaining traction at Complutense University of Madrid
• ·Shinhan to bet big on insurance tech startup
• ·Art Token launches Hangeul
• ·How college students are coping with the impact of inflation
• ·National Theater of Korea's 50th year to close with 'Song of King Sejong'
• ·Performing Arts Market to link local artists to world
• ·Seoul shares open higher on US gains; Israel
• ·낙후된 골목시장 누비며 “화곡을 마곡으로 만들 것”
• ·Fractional art market opens up to lure new investors
• ·N.SSign to resume album promotion without Doha
• ·尹대통령 지지율, 1.1%p 내린 38.9% [알앤써치]
• ·Disney+’s ‘Moving’ sweeps BIFF’s Asia Contents Awards & Global OTT Awards